REGENTIS BIOMATERIALS LTD/IS
RGNTNYSE AMERICANTrading Snapshot
- Day Range
- $1.84 – $1.87
- 52-Week Range
- $1.23 – $15.50
- Volume
- $1.89B
- Avg Volume
- $1.96B
- Shares Outstanding
- 7.0M
- Next Earnings
- Nov 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $665,510
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own RGNT
- ✓High-growth profile — revenue up +33.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 19% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
REGENTIS BIOMATERIALS LTD/IS
RGNT
StockOtter · stockotter.spaceAbout REGENTIS BIOMATERIALS LTD/IS
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the la
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness, including surgeon training and regulatory appr
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting,
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production GelrinC®, which is approved f